Results 181 to 190 of about 123,913 (326)

Identification of a 2-phenyl-substituted octahydrobenzo[f]quinoline as a dopamine D3 receptor-selective full agonist ligand

, 2012
Alia H. Clark, John D. McCorvy, Jason M. Conley, Whitney K. Williams, B. Markondaiah, Val J. Watts, David E. Nichols   +6 more
openalex   +2 more sources

Psilocybin as a novel treatment for chronic pain

British Journal of Pharmacology, EarlyView.
Abstract Psychedelic drugs are under active consideration for clinical use and have generated significant interest for their potential as anti‐nociceptive treatments for chronic pain, and for addressing conditions like depression, frequently co‐morbid with pain.
Tate Askey, Reena Lasrado, Maria Maiarú, Gary J. Stephens   +3 more
wiley   +1 more source

Modulatory Effects of Dopamine D2 Receptors on Spreading Depression in Rat Somatosensory Neocortex

Basic and Clinical Neuroscience, 2014
Introduction: Spreading depression (SD) is a propagating wave of depolarization followed by depression of the neuroglial activities and can modulate extracellular dopamine concentrations in the neocortex.
Anna Maria Haarmann, Maryam Jafarian, Fariba Karimzadeh, Ali Gorji   +3 more
doaj  

Altered Pain Processing Associated with Administration of Dopamine Agonist and Antagonist in Healthy Volunteers. [PDF]

Brain Sci, 2022
Martin SL, Jones AKP, Brown CA, Kobylecki C, Whitaker GA, El-Deredy W, Silverdale MA.   +6 more
europepmc   +1 more source

A Comparison of Short and Long-Term Acting Dopamine Agonists in the Treatment of Parkinson’s Disease with Respect to the Side Effects of Impulse Control Disorder [PDF]

Hiba Gül Oruc
openalex   +1 more source

Neuropsychopharmacology of hallucinogenic and non‐hallucinogenic 5‐HT2A receptor agonists

British Journal of Pharmacology, EarlyView.
Psychedelic drugs such as LSD and psilocin were once relegated to the fringes of medical research because of their association with counterculture movements and a perceived concern about harm through recreational use, and their consequent legal prohibition in the early 1970s.
Trevor Sharp, Aurelija Ippolito
wiley   +1 more source

¹¹C-methionine PET aids localization of microprolactinomas in patients with intolerance or resistance to dopamine agonist therapy. [PDF]

Pituitary, 2022
Bashari WA, van der Meulen M, MacFarlane J, Gillett D, Senanayake R, Serban L, Powlson AS, Brooke AM, Scoffings DJ, Jones J, O'Donovan DG, Tysome J, Santarius T, Donnelly N, Boros I, Aigbirhio F, Jefferies S, Cheow HK, Mendichovszky IA, Kolias AG, Mannion R, Koulouri O, Gurnell M.   +22 more
europepmc   +1 more source

The Beta-Arrestin-Biased Dopamine D2 Receptor Ligand, UNC9994, Is a Partial Agonist at G-Protein-Mediated Potassium Channel Activation [PDF]

, 2018
Richard Ågren, Peter Århem, Johanna Nilsson, Kristoffer Sahlholm   +3 more
openalex   +1 more source

(±)VK4‐40, a novel dopamine D₃ receptor partial agonist, attenuates cocaine reward and relapse in rodents [PDF]

, 2020
Chloe J. Jordan, Yi He, Guo‐Hua Bi, Zhi‐Bing You, Jianjing Cao, Zheng‐Xiong Xi, Amy Hauck Newman   +6 more
openalex   +1 more source

Psychedelics, entactogens and psychoplastogens for depression and related disorders

British Journal of Pharmacology, EarlyView.
Currently, the most actively investigated rapidly acting antidepressants, anxiolytics and/or anti PTSD agents, include psychedelics e.g. psilocybin, LSD, N,N‐dimethyltryptamine, ayahuasca; non‐hallucinogenic entactogens, e.g. MDMA; psychoplastogens which rapidly promote neuroplasticity, e.g.
Daniel Hoyer
wiley   +1 more source